Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 01, 2026
TickeronGET DAILY SIGNALS
Why Is Glass House Brands (GLAS) Stock Down -7.66% Today?

Why Is Glass House Brands (GLAS) Stock Down -7.66% Today?

Key Takeaways

  • GLAS shares fell about 7.66% to $5.18, down from the prior session's close of $5.61.
  • The primary catalyst was a sector-wide cannabis selloff after a DEA judge paused the marijuana rescheduling process.
  • A secondary driver was Glass House Brands' announcement of its chief financial officer's planned retirement.
  • The move extends a multi-week slide that has pushed the stock near its 52-week low.
  • Traders are now watching the DEA's mid-October response and the company's next earnings report in November.

Opening Summary

Glass House Brands Inc. (GLAS), an integrated, California-focused cannabis company that cultivates, manufactures, and distributes products under brands such as Glass House Farms, PLUS, Allswell, and Mama Sue, extended its sharp decline in Thursday's trading session. The stock was down roughly 7.66%, trading near $5.18 compared with the prior close of $5.61, continuing a punishing stretch for cannabis equities. Markets pointed primarily to a federal regulatory setback for the industry as a whole, compounded by a leadership transition announcement at the company itself.

Sector-Wide Selloff After DEA Rescheduling Pause

The dominant force behind the decline was a broad risk-off move across cannabis stocks. A Drug Enforcement Administration (DEA) administrative law judge paused the pending proceeding on moving marijuana from Schedule I to Schedule III, following a Government Accountability Office report that flagged gaps in the federal scheduling process. The judge granted a stay requested by parties opposing broader rescheduling and gave the DEA until October 13 to respond on whether to reopen the record.

Investors had treated rescheduling as a near-term catalyst because Schedule III status would lift the onerous Section 280E tax penalty, allowing operators to deduct ordinary business expenses and materially improving earnings and cash flow. The procedural pause pushed expectations for progress further out and triggered heavy selling across multi-state operators and cannabis-focused ETFs. GLAS fell in sympathy with peers such as TRLV and the MSOS ETF, as investors repriced the timeline for federal reform.

CFO Retirement Adds Company-Specific Uncertainty

Compounding the sector pressure, Glass House Brands announced on September 29 the planned retirement of Chief Financial Officer Mark Vendetti, who will remain in the role through March 31, 2027 while the company searches for a successor. Executive departures in the finance function can weigh on sentiment, particularly for a company navigating margin compression and a shrinking revenue base. The announcement added a layer of company-specific uncertainty to an already fragile tape.

Fundamental Backdrop Remains Challenging

The selloff also reflects underlying operational headwinds. In its second quarter, Glass House Brands reported revenue of about $47 million, below prior guidance, in part due to the deconsolidation of retail operations. Gross margin declined sharply versus the prior year as a higher mix of low-value trim sales and elevated production costs pressured profitability. The company generates the bulk of its revenue from low-margin wholesale biomass, and its branded consumer segment remains a small fraction of the business. These fundamentals left the stock vulnerable when regulatory sentiment soured.

Market Context and Trading Activity

Trading activity reflected the intensity of the move. The prior session's volume of more than 5.5 million shares was roughly ten times the stock's average daily volume, signaling broad-based selling rather than isolated positioning. The decline has brought GLAS to the lower end of its range, near its 52-week low around $5.15, and well below its 50-day and 200-day moving averages. The move diverged from the broader equity market, underscoring that the pressure was specific to cannabis and regulatory sentiment rather than a macro-driven risk-off event.

What Comes Next for GLAS

Investors will be watching the DEA's October 13 response on whether the rescheduling record will be reopened, a decision that could set the tone for the sector into the fall. Glass House Brands is also expected to report its next quarterly results on November 11, 2026, with attention on biomass pricing, margin recovery, and any update on the CFO succession process. The company's elevated debt and preferred-stock obligations remain a focus, as does the timeline for interstate and international expansion. Until there is clearer regulatory visibility or a firmer fundamental inflection, volatility in the stock is likely to persist.

Trending AI Robots

For traders seeking a more systematic approach to fast-moving markets, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI trading bots. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, but only those performing best under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of options to explore. Visit the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLAS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GLAS in +30.71% Uptrend, advancing for three consecutive days on November 17, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GLAS advanced for three days, in 199 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 28 of 36 cases over the following month. The odds of a continued upward trend are 78%.

GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 73 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for GLAS entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3645 Long Beach Boulevard
Phone
+1 212 299-7670
Employees
428
Web
https://www.glasshousebrands.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.